Many are called, few are chosen: the role of science in drug development decisions

Article; Early Access

关键词: RESEARCH-AND-DEVELOPMENT;    PHARMACEUTICAL-INDUSTRY;    BASIC RESEARCH;    DEVELOPMENT PRODUCTIVITY;    ABSORPTIVE-CAPACITY;    SCIENTIFIC-RESEARCH;    STAR SCIENTISTS;    VALUE-CREATION;    ANIMAL-MODELS;    INNOVATION;   

DOI  :  10.1007/s10961-022-09982-6

来源: SCIE

【 摘 要 】

Pharmaceutical firms are extremely selective in deciding which patented drug candidates are taken up into clinical development, given the high costs and risks involved. We argue that the scientific base of drug candidates, and who was responsible for that scientific research, are key antecedents of take-up into clinical trials and whether the patent owner ('internal take-up') or another firm ('external take-up') leads the clinical development effort. We hypothesize that patented drug candidates that refer to scientific research are more likely to be taken up in development, and that in-house conducted scientific research is predominantly associated with internal take-up due to the ease of knowledge transfer within the firm. Examining 18,360 drug candidates patented by 136 pharmaceutical firms we find support for these hypotheses. In addition, drug candidates referring to in-house scientific research exhibit a higher probability of eventual drug development success. Our findings underline the importance of a 'rational drug design' approach that explicitly builds on scientific research. The benefits of internal scientific research in clinical development highlight the potential downside of pervasive organizational specialization in the life sciences in either scientific research or clinical development.

【 授权许可】

Free